> Details
Herbst, Sophie
[Author];
Vesterlund, Mattias
[Author];
Helmboldt, Alexander
[Author];
Jafari, Rozbeh
[Author];
Siavelis, Ioannis
[Author];
Stahl, Matthias
[Author];
Schitter, Eva C.
[Author];
Liebers, Nora
[Author];
Brinkmann, Berit J.
[Author];
Czernilofsky, Felix
[Author];
Roider, Tobias
[Author];
Bruch, Peter-Martin
[Author];
Iskar, Murat
[Author];
Kittai, Adam
[Author];
Huang, Ying
[Author];
Lu, Junyan
[Author];
Richter, Sarah
[Author];
Mermelekas, Georgios
[Author];
Umer, Husen Muhammad
[Author];
Knoll, Mareike
[Author];
Kolb, Carolin
[Author];
Lenze, Angela
[Author];
Cao, Xiaofang
[Author];
Österholm, Cecilia
[Author];
[...]
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
Sharing
Reference
management
Direct link
Bookmarks
Remove from
bookmarks
Share this by email
Share this on Twitter
Share this on Facebook
Share this on Whatsapp
- Media type: E-Article
- Title: Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
- Contributor: Herbst, Sophie [VerfasserIn]; Vesterlund, Mattias [VerfasserIn]; Helmboldt, Alexander [VerfasserIn]; Jafari, Rozbeh [VerfasserIn]; Siavelis, Ioannis [VerfasserIn]; Stahl, Matthias [VerfasserIn]; Schitter, Eva C. [VerfasserIn]; Liebers, Nora [VerfasserIn]; Brinkmann, Berit J. [VerfasserIn]; Czernilofsky, Felix [VerfasserIn]; Roider, Tobias [VerfasserIn]; Bruch, Peter-Martin [VerfasserIn]; Iskar, Murat [VerfasserIn]; Kittai, Adam [VerfasserIn]; Huang, Ying [VerfasserIn]; Lu, Junyan [VerfasserIn]; Richter, Sarah [VerfasserIn]; Mermelekas, Georgios [VerfasserIn]; Umer, Husen Muhammad [VerfasserIn]; Knoll, Mareike [VerfasserIn]; Kolb, Carolin [VerfasserIn]; Lenze, Angela [VerfasserIn]; Cao, Xiaofang [VerfasserIn]; Österholm, Cecilia [VerfasserIn]; Wahnschaffe, Linus [VerfasserIn]; Herling, Carmen [VerfasserIn]; Scheinost, Sebastian [VerfasserIn]; Ganzinger, Matthias [VerfasserIn]; Mansouri, Larry [VerfasserIn]; Kriegsmann, Katharina [VerfasserIn]; Kriegsmann, Mark [VerfasserIn]; Anders, Simon [VerfasserIn]; Zapatka, Marc [VerfasserIn]; Del Poeta, Giovanni [VerfasserIn]; Zucchetto, Antonella [VerfasserIn]; Bomben, Riccardo [VerfasserIn]; Gattei, Valter [VerfasserIn]; Dreger, Peter [VerfasserIn]; Woyach, Jennifer [VerfasserIn]; Herling, Marco [VerfasserIn]; Müller-Tidow, Carsten [VerfasserIn]; Rosenquist, Richard [VerfasserIn]; Stilgenbauer, Stephan [VerfasserIn]; Zenz, Thorsten [VerfasserIn]; Huber, Wolfgang [VerfasserIn]; Tausch, Eugen [VerfasserIn]; Lehtiö, Janne [VerfasserIn]; Dietrich, Sascha [VerfasserIn]
- imprint: 20 October 2022
- Published in: Nature Communications ; 13(2022) vom: Okt., Artikel-ID 6226, Seite 1-18
- Language: English
- DOI: 10.1038/s41467-022-33385-8
- ISSN: 2041-1723
- Identifier:
- Keywords: Chronic lymphocytic leukaemia ; Computational models ; Proteomic analysis
- Origination:
- Footnote:
- Description: Cancer heterogeneity at the proteome level may explain differences in therapy response and prognosis beyond the currently established genomic and transcriptomic-based diagnostics. The relevance of proteomics for disease classifications remains to be established in clinically heterogeneous cancer entities such as chronic lymphocytic leukemia (CLL). Here, we characterize the proteome and transcriptome alongside genetic and ex-vivo drug response profiling in a clinically annotated CLL discovery cohort (n = 68). Unsupervised clustering of the proteome data reveals six subgroups. Five of these proteomic groups are associated with genetic features, while one group is only detectable at the proteome level. This new group is characterized by accelerated disease progression, high spliceosomal protein abundances associated with aberrant splicing, and low B cell receptor signaling protein abundances (ASB-CLL). Classifiers developed to identify ASB-CLL based on its characteristic proteome or splicing signature in two independent cohorts (n = 165, n = 169) confirm that ASB-CLL comprises about 20% of CLL patients. The inferior overall survival in ASB-CLL is also independent of both TP53- and IGHV mutation status. Our multi-omics analysis refines the classification of CLL and highlights the potential of proteomics to improve cancer patient stratification beyond genetic and transcriptomic profiling.
- Access State: Open Access